Navigation Links
High and Super-High Potency Topical Corticosteroids Will Remain Decision Resources' Clinical Gold Standard Through 2017 for the Treatment of Atopic Dermatitis

A Once-Daily Topical Agent With a Novel Mechanism of Action and Efficacy Advantages Over Elidel Would Earn Higher Patient Share in the U.S. Than in Europe, According to a New Report from Decision Resources

WALTHAM, Mass., Feb. 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that high and super-high potency topical corticosteroids (TCSs) will remain Decision Resources' proprietary clinical gold standard through 2017 for the treatment of atopic dermatitis. While some therapies in development for the disease hold promise, most have efficacy, safety and tolerability and/or delivery issues.

"Although efficacious drugs like high and super-high potency TCSs are available, they are predominantly used to treat adult patients with severe atopic dermatitis," stated Kyle Crowell, analyst at Decision Resources. "For pediatric and adult patients with less severe atopic dermatitis, physicians prefer to prescribe drugs with superior safety profiles. Improvements in safety and tolerability would provide a competitive advantage for an emerging atopic dermatitis drug."

The new report entitled Atopic Dermatitis: A Market with Well-Established First-Line Agents Still Needs a Safe Maintenance Therapy also finds that a once-daily topical agent with a novel mechanism of action and efficacy advantages over Novartis' Elidel would earn 35 percent patient share in the atopic dermatitis drug market, according to surveyed U.S. dermatologists. On the other hand, in Europe, such an agent would earn a 25 percent patient share, according to surveyed European dermatologists.

About the Report

Atopic Dermatitis: A Market with Well-Established First-Line Agents Still Needs a Safe Maintenance Therapy is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

    Natalia Morales                        Elizabeth Marshall
    Decision Resources                     Decision Resources, Inc.
    781-296-2691                           781-296-2563      

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. SAFC Pharma(TM) Commits to Major Expansion of High Potency API Production at Madison Site
2. Triax Pharmaceuticals Launches New Mid-Potency Corticosteroid Vehicle, Locoid Lotion 0.1%
3. Bariatric Advantage Announces New Higher-Potency Iron Supplement for Weight Loss Surgery Patients
4. Novel molecules developed at UB can boost vaccine potency
5. Nordic Naturals Professional Exclusive Division Redefines High Potency Omega-3 Supplementation With New Elite Line!
6. Galderma Wins FDA Approval for Vectical(TM) Ointment, a Novel Topical Therapy for Mild-to-Moderate Plaque Psoriasis
7. Ready-To-Use Products Spur the European Tissue Sealants and Topical Hemostats Markets, Says Frost & Sullivan
8. New topical approach to treating nail fungus circumvents problems with current therapy
9. Topical treatment for cold sores achieves efficacy of oral drugs; represents paradigm shift
10. Topical oral syrup prevents early childhood caries
11. Nuvo licenses topical pain product from Paladin
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... TyloHelo ... parts and accessories. , Sauna accessories help improve the bather experience in the ... From basic styles for the purist looking for simplicity in design to accessories ...
(Date:11/25/2015)... ... 2015 , ... For the first time, Vitalalert is donating half of its ... The partnership between the two groups began in 2014 with Vitalalert pledging a portion ... International was founded in 1954 and is an international Christian-based health organization whose mission ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 25, 2015, ... for the Narconon network, announced the release of a new cutting edge recovery program ... organization has been working with drug- and alcohol-addicted individuals with the purpose to free ...
(Date:11/25/2015)... ... November 25, 2015 , ... Smiles by Stevens ... Disorder, Bruxism, and moderate facial wrinkling. While many patients are aware of the benefits ... great success Botox® delivers to those suffering with discomfort, soreness, and pain as a ...
(Date:11/25/2015)... Livonia, MI (PRWEB) , ... November 25, 2015 , ... ... at Presence Resurrection Medical Center (RMC) in Chicago, IL, UV Angel is evaluating the ... the medical and surgical intensive care units (totaling 30 beds) from May 2014 through ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the European Therapeutic Drug Monitoring ... Forecasts, Competitive Intelligence, Emerging Opportunities"  report ... ) has announced the addition ...
(Date:11/26/2015)... November 26, 2015 ... addition of the  "2016 Future Horizons ... Cell Surface Marker Testing Market: Supplier ... to their offering.  --> ... of the  "2016 Future Horizons and ...
(Date:11/25/2015)... WOODBURY, N.Y. , Nov. 25, 2015  Linden ... access and optimizing treatment outcomes for patients suffering from ... its request for a Temporary Restraining Order (TRO) enjoining ... between the two companies. --> ... aggressively pursuing all of its legal options. ...
Breaking Medicine Technology: